Loading
A phase 1/2 trial of Olaparib, Ipilimumab and Nivolumab in triple-negative breast cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Lantern Pharma Inc., active and no longer recruiting.
Study of LP-184 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05933265 by Lantern Pharma Inc., with 64 participants enrolled, started 2023-06-09 and due to reach its primary completion in 2026-07-28. Interventions recorded: LP-184, Olaparib and Nivolumab & Ipilimumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lantern Pharma, Non-small-cell lung cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Ipilimumab, Nivolumab and the tag pipeline.
Shares Ipilimumab, Nivolumab and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Ipilimumab, Nivolumab and the tag pipeline.
Shares Ipilimumab, Nivolumab and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/